GLORIA

GEOMAR Library Ocean Research Information Access

X
You have 0 saved results.
Mark results and click the "Add To Watchlist" link in order to add them to this list.
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Online Resource
    Online Resource
    Tumors of the Brain and Spine (2006)
    Norwell : Springer Science+Business Media, LLC
    Details Availability
    Keywords: Medicine ; Neurology ; Neurosurgery ; Oncology ; Cancer Surgery ; Pathology ; Medicine & Public Health ; Cancer Surgery ; Neurology ; Neurosurgery ; Oncology ; Pathology ; Medicine ; Brain Neoplasms ; Spinal Cord Neoplasms ; Brain Neoplasms therapy ; Spinal Cord Neoplasms therapy ; Aufsatzsammlung ; Hirntumor ; Wirbelsäule ; Tumor ; Hirntumor ; Rückenmarkstumor
    Description / Table of Contents: Focuses on the standard approaches to the treatment of benign, primary low-grade to high-grade, and metastatic tumors in the brain and spine used by surgeons and clinicians at the University of Texas M D Anderson Cancer Center
    Type of Medium: Online Resource
    Pages: Online-Ressource (XII, 364 p. 73 illus, digital)
    ISBN: 9780387292021
    Series Statement: M. D. Anderson Cancer Care Series
    URL: https://doi.org/10.1007/978-0-387-29202-1
    URL: http://dx.doi.org/10.1007/978-0-387-29202-1
    URL: https://swbplus.bsz-bw.de/bsz266999069kap.htm
    URL: https://swbplus.bsz-bw.de/bsz266999069vor.htm
    URL: https://swbplus.bsz-bw.de/bsz266999069cov.jpg
    URL: https://swbplus.bsz-bw.de/bsz266999069inh.htm
    URL: http://www.gbv.de/dms/bowker/toc/9780387292014.pdf
    DOI: 10.1007/978-0-387-29202-1
    RVK:
    XH 8550
    RVK:
    XH 8600
    Language: English
    Note: Description based upon print version of record , Front Matter; Epidemiology of Brain Tumors; Neuropathology and Molecular Biology of Intracranial Tumors; Radiology of Brain Tumors: Structure and Physiology; Surgically Curable Brain Tumors of Adults; Low-Grade Gliomas: Evidence-Based Treatment Options; Surgical Strategies for High-Grade Gliomas; Radiation Oncology for Tumors of the Central Nervous System: Improving the Therapeutic Index; Cytotoxic Chemotherapy for Diffuse Gliomas; Innovative Treatment Strategies for High-Grade Gliomas; Pituitary Tumors in Oncology , Management of Lung Cancer, Breast Cancer, and Melanoma Metastatic to the BrainNeoplastic Meningitis; Lymphoma Affecting the Central Nervous System; Tumors of the Extradural Spine; Tumors of the Spinal Cord and Intradural Space; Symptom Management for Patients with Brain Tumors: Improving Quality of Life; Back Matter;
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    GEOMAR CATALOGUE
    Link to Library Catalog
    get availability status
  • 2
    Electronic Resource
    Electronic Resource
    Fluorouracil, Doxorubicin, and Cyclophosphamide Followed by Tamoxifen as Adjuvant Treatment for Patients with Stage IV Breast Cancer with No Evidence of Disease (2002)
    Boston, MA, USA : Blackwell Science Inc
    The @breast journal 8 (2002), S. 0 
    Details
    ISSN: 1524-4741
    Source: Blackwell Publishing Journal Backfiles 1879-2005
    Topics: Medicine
    Notes: We conducted a single-institution study to determine whether local therapy plus six cycles of chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) followed by 5 years of tamoxifen is superior to local treatment alone in terms of disease-free survival (DFS) and overall survival (OS) in patients with stage IV breast cancer with no evidence of disease (stage IV-NED breast cancer). Patients with breast cancer were eligible if they had histologic proof of a locoregional or distant recurrence that had been curatively resected, irradiated, or both and had no other evidence of disease. Patients who had received prior anthracycline therapy were not eligible. All patients received six cycles of intravenous FAC, with cycles repeated every 3 weeks. After completion of chemotherapy, patients whose tumors had not previously demonstrated resistance to tamoxifen and had positive or unknown estrogen receptor status received tamoxifen 20 mg by mouth daily for 5 years. Patients in this study were compared with a historical control population (patients with stage IV-NED breast cancer who never received systemic therapy) as well as with the patients in two previously reported trials of chemotherapy for stage IV-NED disease. Forty-seven patients were registered, but only 45 were evaluable. There was a highly statistically significant difference ( p 〈 0.001) in OS and DFS among the four groups, with patients in our most recent study having the best OS and DFS at 3 years compared with the control group (84% vs. 55% and 66% vs. 11%, respectively). When patients in all four groups were analyzed together in search of prognostic factors, we found that patients whose primary tumors had negative axillary lymph nodes had a statistically significant improvement in OS and DFS (p 〈 0.01) compared with patients with positive axillary lymph nodes. No survival differences were found between patients with positive and those with negative hormone receptor status. This study demonstrates a benefit in terms of OS and DFS for patients with stage IV-NED breast cancer who receive doxorubicin-based adjuvant chemotherapy. The benefit was greater on patients with node-negative primary tumors. In patients with stage IV-NED disease, doxorubicin-based chemotherapy should be considered standard treatment after adequate local control is achieved.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1046/j.1524-4741.2002.08002.x
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    A Roundtable Discussion of Aromatase Inhibitors as Therapy for Breast Cancer (2003)
    Oxford, UK : Blackwell Science Inc
    The @breast journal 9 (2003), S. 0 
    Details
    ISSN: 1524-4741
    Source: Blackwell Publishing Journal Backfiles 1879-2005
    Topics: Medicine
    Notes: Abstract:  This article summarizes the conclusions of a meeting of diverse breast cancer experts who discussed issues, controversies, and new clinical trial results relevant to the use of aromatase inhibitors for treating postmenopausal women with breast cancer. The new generation of aromatase inhibitors (anastrozole, letrozole, exemestane) have largely replaced megestrol acetate as a second-line therapy in postmenopausal women with hormone-responsive advanced breast cancer. In addition, anastrozole and letrozole have been shown to be superior to tamoxifen for first-line therapy. Finally, recent results suggest that anastrozole may be superior to tamoxifen as adjuvant therapy for early stage disease in postmenopausal women with hormone-responsive disease.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1046/j.1524-4741.2003.09305.x
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 4
    Electronic Resource
    Electronic Resource
    Efficacy of Anastrozole in a Consecutive Series of Advanced Breast Cancer Patients Treated with Multiple Prior Chemotherapies and Endocrine Agents: M. D. Anderson Cancer Center Experience (1999)
    Boston, MA, USA : Blackwell Science Inc
    The @breast journal 5 (1999), S. 0 
    Details
    ISSN: 1524-4741
    Source: Blackwell Publishing Journal Backfiles 1879-2005
    Topics: Medicine
    Notes: ▪ Abstract: Anastrozole is a highly selective, nonsteroidal aromatase inhibitor approved by the U.S. Food and Drug Administration (FDA) in January 1996 for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. To date, information on anastrozole’s use has been limited to breast cancer patients with minimal prior therapy. The purpose of this review was to determine, in clinical practice, the benefits of anastrozole in advanced breast cancer patients treated with multiple prior cytotoxic and endocrine therapies. This was a retrospective review of a consecutive series of 117 patients who received anastrozole after marketing in January 1996. As this was not a prospective study, rigorous response criteria could not be applied. Responses were categorized as improvement in disease (ID), stable disease (SD), or progressive disease (PD). One hundred eight patients were evaluable for response with a median age of 61 years and the number of prior therapies ranging from one to nine. Response, defined as improvement of disease or stable disease 〈inlineGraphic alt="geqslant R: gt-or-equal, slanted" extraInfo="nonStandardEntity" href="urn:x-wiley:1075122X:TBJ98055:ges" location="ges.gif"/〉8 weeks, was seen in 59% of patients. Patients with three or more prior endocrine therapies demonstrated a 61% response (ID + SD) and patients with ER-negative tumors demonstrated 50% response. Patients with prior aminoglutethamide therapy exhibited similar response rates to the overall group. One male patient received anastrozole without benefit. This data determines the activity of anastrozole even in heavily pretreated patients and suggests that patients who have tumors that are ER-negative may also benefit from anastrozole therapy. ▪
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1046/j.1524-4741.1999.98055.x
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 5
    Electronic Resource
    Electronic Resource
    Inflammatory Breast Cancer: Clinical Features and the Role of Multimodality Therapy (1996)
    Oxford, UK : Blackwell Publishing Ltd
    The @breast journal 2 (1996), S. 0 
    Details
    ISSN: 1524-4741
    Source: Blackwell Publishing Journal Backfiles 1879-2005
    Topics: Medicine
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1111/j.1524-4741.1996.tb00119.x
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 6
    Electronic Resource
    Electronic Resource
    The Impact of Hormone Receptor Status on the Clinical Efficacy of the New-Generation Aromatase Inhibitors: A Review of Data from First-Line Metastatic Disease Trials in Postmenopausal Women (2004)
    Oxford, UK : Blackwell Science Inc
    The @breast journal 10 (2004), S. 0 
    Details
    ISSN: 1524-4741
    Source: Blackwell Publishing Journal Backfiles 1879-2005
    Topics: Medicine
    Notes: Abstract:  Hormone receptor status has long been considered important in predicting the efficacy of endocrine agents for the treatment of breast cancer. We aim to address whether hormone receptor status influences treatment outcome in postmenopausal women receiving aromatase inhibitors for advanced breast cancer. We include data from three phase III clinical trials, comparing the activity of the new-generation aromatase inhibitors, anastrozole or letrozole, with tamoxifen as a first-line treatment. For both agents, a significant relationship was observed between hormone receptor status and time to disease progression (TTP), with increased TTP seen in patients with a higher confirmed percentage of estrogen receptor (ER)- and/or progesterone receptor (PR)-positive tumors. A relationship between objective response rate (complete or partial response) or clinical benefit (complete or partial response or stabilization for ≥24 weeks) and hormone receptor status was apparent for anastrozole but not letrozole treatment. Overall these data confirm that hormone receptor status should be a strong consideration in the selection of endocrine treatment for postmenopausal women with advanced breast cancer. 
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1111/j.1075-122X.2004.21320.x
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 7
    Electronic Resource
    Electronic Resource
    Hormonal Therapy in Early and Advanced Breast Cancer (2004)
    Oxford, UK : Blackwell Science Inc
    The @breast journal 10 (2004), S. 0 
    Details
    ISSN: 1524-4741
    Source: Blackwell Publishing Journal Backfiles 1879-2005
    Topics: Medicine
    Notes: Abstract:  While some of the most intriguing data on the development of hormonal therapy for breast cancer have come from studies on aromatase inhibitors (AIs), few trials have compared these agents directly, with the exception of the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial. Based on the latest results from this trial and on previous investigations of other AIs, a proposed sequence of hormonal therapies (including anastrozole, tamoxifen, letrozole, fulvestrant, and megestrol acetate) for the treatment of breast cancer is beginning to emerge for various patient populations.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1111/j.1524-4741.2004.101S7.x
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 8
    Electronic Resource
    Electronic Resource
    Response to Induction Chemotherapy in Black and White Patients with Locally Advanced Breast Cancer (2000)
    Boston, MA, USA : Blackwell Science Inc
    The @breast journal 6 (2000), S. 0 
    Details
    ISSN: 1524-4741
    Source: Blackwell Publishing Journal Backfiles 1879-2005
    Topics: Medicine
    Notes: Abstract: Black women with breast cancer have significantly poorer survival rates, a more advanced stage distribution, and are diagnosed at younger ages compared to white patients in the United States. We evaluated tumor response and survival with respect to race and age after induction chemotherapy. The study population consisted of 303 patients (229 white, 74 black) registered in two prospective trials of induction chemotherapy for locally advanced breast cancer [stage II (T 〈inlineGraphic alt="geqslant R: gt-or-equal, slanted" extraInfo="nonStandardEntity" href="urn:x-wiley:1075122X:TBJ99071:ges" location="ges.gif"/〉 4 cm), stage III (noninflammatory), and stage IV (supraclavicular lymph node involvement only)] between 1989 and 1996. Chemotherapy regimens utilized 5-fluorouracil, cyclophosphamide, and doxorubicin (FAC). Response was defined as complete (CR, no clinical/radiographic detectable disease), partial (PR, 〈inlineGraphic alt="geqslant R: gt-or-equal, slanted" extraInfo="nonStandardEntity" href="urn:x-wiley:1075122X:TBJ99071:ges" location="ges.gif"/〉50% reduction in disease), minor (MR, 〈50% reduction), no change (NC), or progressive disease (PD). Median follow-up was 58 months; survival was calculated using the Kaplan–Meier method. There was no significant difference in age at presentation (54% of black patients compared to 58% of white patients 〈50 years of age). The black patients had significantly more advanced stages of disease at diagnosis (50% of black patients compared to 30% of white patients with stage IIIB disease; p = 0.03). For both age groups together, tumor response, 5-year overall survival (OS), and 5-year disease-free survival (DFS) rates were similar between the black and white patients. A trend was noted that the younger black patients were more likely to have a clinical CR or PR; this did not translate into a survival advantage. Despite the more advanced stage distribution for black women with breast cancer, induction chemotherapy yields high response rates (especially for younger black patients) and survival rates equivalent to white patients.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1046/j.1524-4741.2000.99071.x
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 9
    Electronic Resource
    Electronic Resource
    Management of inflammatory breast cancer (1994)
    Springer
    World journal of surgery 18 (1994), S. 87-92 
    Details
    ISSN: 1432-2323
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Résumé Le cancer du sein inflammatoire (CSI) est rare mais souvent fatal. Les auteurs concluent que: 1) le diagnostic du CSI est basé sur la triade clinique: érythème, phénomène de peau d'orange et début rapide. L'importance de l'envahissement ganglionnaire est controversée; 2) la chimiothérapie combinée, comportant au moins la doxorubicine, associée à une mastectomie ou à la radiothérapie, améliore le pronostic par rapport à la mastectomie ou la radiothérapie seules; 3) la mastectomie après chimiothérapie d'induction peut parfois ne pas améliorer le pronostic ni diminuer le taux de récidives locorégionales. La chirurgie fournit, cependant, des données essentielles au plan pronostic, basées aussi sur la réponse thérapeutique et permet d'utiliser des doses de radiothérapie moindres par la suite, réduisant ainsi le taux de complications à long terme; 4) le nombre de cycles et les doses de chimiothérapie optimaux ne sont pas encore bien définis dans le CSI.
    Abstract: Resumen El cáncer inflamatorio del seno (CIS) es una enfermedad rara pero generamente letal. La presente revisión se refiere a las siguientes conclusiones: (1) El diagnóstico del CIS se fundamenta en la tríada de eritema, “piel de naranja” y un comienzo rápido de la enfermedad. La importancia de la evidencia histológica de invasión de los linfáticos dérmicos, como criterio diagnóstico, es motivo de controversia. (2) La combinación de un régimen quimioterápico que contenga doxorrubicina con mastectomía o radioterapia mejora la sobrevida, en comparación con lo que logran la mastectomía o la irradiación solas. (3) Aunque es posible que con la mastectomía que se practica luego de la quimioterapia de inducción no se logre mejoría de la sobrevida ne disminuir las tasas de recurrencial local-regional, la cirugía provee importante información de carácter pronóstico en relación a la respuesta al tratamiento y permite, ulteriormente, el uso de dosis más bajas de irradicación, lo cual resulta en una reducción de las complicaciones a largo plazo. (4) El número óptimo de ciclos y la intensidad de las dosis de quimioterapia en el CIS todavía no han sido definidas.
    Notes: Abstract Inflammatory breast cancer (IBC) is a rare but often fatal disease. This review discusses the following conclusions: (1) The diagnosis IBC is based on the clinical triad of erythema, ridging with peau d'orange, and rapid onset. The importance of histologic evidence of dermal lymphatic involvement is controversial. (2) Combining doxorubicin-containing chemotherapy with mastectomy or radiation therapy improves survival over that achieved with mastectomy or irradiation alone. (3) Mastectomy after induction chemotherapy may not improve survival or decrease locoregional recurrence rates, but the surgery does provide important prognostic information on treatment response and enables use of a lower radiation dose afterward, which results in reduced long-term complications. (4) The optimal number of cycles and dose intensity of chemotherapy for IBC remain undefined.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00348197
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 10
    Electronic Resource
    Electronic Resource
    Phase I trail of droloxifene in patients with metastatic breast cancer (1994)
    Springer
    Cancer chemotherapy and pharmacology 33 (1994), S. 313-316 
    Details
    ISSN: 1432-0843
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Droloxifene (3-hydroxytamoxifen) is a new, nonsteroidal antiestrogen. In comparison with tamoxifen, it has a 10-to 64-fold higher affinity for the estrogen receptor and has shown a lower estrogenic and higher antiestrogenic effect in experimental studies. The objective of this study was to determine the toxicity (and its reversibility) of droloxifene given at different doses to patients with advanced metastatic breast cancer refractory to conventional endocrine therapy and chemotherapy. In this study, 30 patients were treated in groups of 6 at 5 different doses (20, 40, 100, 200, and 300 mg) by mouth once a day. Toxic effects included hot flashes, nausea, and fatigue and were not dose-related. Toxicity did not require any dose reduction or discontinuation of therapy. There was one episode of deep venous thrombosis and pulmonary embolism. There was no complete or partial response in this study, but four patients showed a minor response (13%). These data illustrate that this drug is well tolerated and needs to be further evaluated in phase II and III studies.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00685906
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...